Log in
Enquire now
‌

US Patent 10266592 Drug regulated transgene expression

Patent 10266592 was granted and assigned to Seattle Children's on April, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Seattle Children's
Seattle Children's
0
Current Assignee
Seattle Children's
Seattle Children's
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
102665920
Patent Inventor Names
Michael C. Jensen0
Date of Patent
April 23, 2019
0
Patent Application Number
153024150
Date Filed
April 8, 2015
0
Patent Citations Received
0
‌
US Patent 11408005 Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
‌
US Patent 11414486 Transgene genetic tags and methods of use
0
‌
US Patent 11944648 Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
0
‌
US Patent 11458167 Bispecific CAR T-cells for solid tumor targeting
0
‌
US Patent 10865242 Method and compositions for cellular immunotherapy
Patent Primary Examiner
‌
Kevin K Hill
0
Patent abstract

The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter. Controlling the expression of the chimeric receptor provides for the ability to turn expression on and off depending on the status of the patient. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10266592 Drug regulated transgene expression

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us